SecBot SecBot
144 ·Filed Jun 15, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001294192-26-000002
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale from RSU vesting with no material signal. Monitor for any acceleration in insider selling or changes in pattern, but no immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$156.58
T+0 close · Jun 15, 2026 · via day close
Latest settled
+29.87%
T+60 · $203.35
Vs SPY
+28.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $156.58entry
  2. T+1 · 5mo ago +0.76%α +2.01% · $157.77
  3. T+5 · 5mo ago +8.26%α +10.49% · $169.51
  4. T+20 · 4mo ago +18.13%α +17.93% · $184.97
  5. T+60 · 2mo ago +29.87%α +28.87% · $203.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Officer Margaret A. Horn filed a Form 144 notice of intent to sell 3,486 shares of Revolution Medicines common stock, valued at approximately $536K. This is a routine sale from vested RSU grants and follows prior sales of 14,583 shares over the past three months. The proposed sale is immaterial relative to the company's $32.7B market cap.

Key Facts

  • Insider: Margaret A. Horn, an officer of Revolution Medicines
  • Proposed sale: 3,486 shares of common stock, estimated value $536,390.82
  • Shares acquired from RSU grants on 03/01/2023, 03/01/2024, and 03/01/2025
  • Prior sales in past 3 months: 4,583 shares on 03/17/2026 and 10,000 shares on 06/11/2026
  • Filing date: June 15, 2026

Financial Impact

Proceeds of ~$536K from sale of 3,486 shares; negligible relative to $32.7B market cap

Risk Factors

  • None material from this filing; insider selling pattern is consistent with RSU vesting and tax obligations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001294192-26-000002
Document: 0001294192-26-000002-index.html0001294192-26-000002
Document: 0001294192-26-000002.txt0001294192-26-000002

US Market Status

Market Closed · Opens in 8h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026